Biomerica, Inc. (BMRA), a biomedical company and provider of Contract Development and Manufacturing Organization (CDMO) services for healthcare market, has entered into a Master Services Agreement or MSA with a private life science company to develop proprietary in vitro diagnostic (IVD) assays.
The deal offers an initial development target fee of over $1.75 million through several statements of work (SOWs).
The contract initially is for three years, with automatic one-year renewal.
All the development activities under the agreement will be carried out at Biomerica's FDA-licensed facility. BMRA is currently trading at $2.36, down 2.88%
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.